You are here: Home: CCU 2 | 2003: James L Abbruzzese, MD: Select publications

Select publications

Publications discussed by Dr Abbruzzese

Cartwright TH et al. Phase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancer. J Clin Oncol 2002;20(1):160-4. Abstract

DeGramont A et al. Oxaliplatin/5-FU/LV in adjuvant colon cancer: Results of the international randomized mosaic trial. Proc ASCO 2003. Abstract 1015.

Goldberg RM et al. N9741: Oxaliplatin (oxal) or CPT-11 + 5-fluorouracil (5FU)/leucovorin (LV) or oxal + CPT-11 in advanced colorectal cancer (CRC). Initial toxicity and response data from a GI Intergroup study. Proc ASCO 2002. Abstract 511.

Goldberg RM et al. N9741: Oxaliplatin (oxal) or CPT-11 + 5-fluorouracil (5FU)/leucovorin (LV) or oxal + CPT-11 in advanced colorectal cancer (CRC). Updated efficacy and quality of life (QOL) data from an intergroup study. Proc ASCO 2003. Abstract 1009.

Capecitabine plus oxaliplatin trials

Borner MM et al. Phase II study of capecitabine and oxaliplatin in first- and second-line treatment of advanced or metastatic colorectal cancer. J Clin Oncol 2002;20(7):1759-66. Abstract

Carreca I et al. Oral capecitabine plus oxaliplatin (XELOX regimen) in elderly patients with advanced colorectal carcinoma (ACC). Southern Italy Cooperative Oncology Group (SICOG 0108) Phase II study. Proc ASCO 2003. Abstract 2939.

Coutinho AK, Rocha Lima CM. Metastatic colorectal cancer: Systemic treatment in the new millennium. Cancer Control 2003; 10(3):224-38. Abstract

Diaz-Rubio E et al. Capecitabine (Xeloda) in combination with oxaliplatin: A Phase I, dose-escalation study in patients with advanced or metastatic solid tumors. Ann Oncol 2002;13(4):558-65. Abstract

Grothey A et al. Randomized Phase II trial of capecitabine plus irinotecan (CapIri) vs capecitabine plus oxaliplatin (CapOx) as first-line therapy of advanced colorectal cancer (ACRC). Proc ASCO 2003. Abstract 1022.

Hoff PM. Practical considerations in the use of oral fluoropyrimidines. Semin Oncol 2003; 30(3 Suppl 6):88-92. Abstract

Makatsoris T et al. A Phase II study of capecitabine and oxaliplatin as first-line treatment for advanced colorectal carcinoma (CRC). A Hellenic Cooperative Oncology Group (HeCOG) study. Proc ASCO 2003. Abstract 1447.

Petrovic Z et al. Oxaliplatin (L-OHP) and capecitabine (X) as second-line chemotherapy in patients with advanced gastric cancer. Proc ASCO 2003. Abstract 1199.

Scheithauer W et al. Intermittent weekly high-dose capecitabine in combination with oxaliplatin: A Phase I/II study in first-line treatment of patients with advanced colorectal cancer. Ann Oncol 2002;13(10):1583-9. Abstract

Scheithauer W et al. Randomized multicenter Phase II trial of two different schedules of capecitabine plus oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2003; 21(7):1307-12. Abstract

Thomas RR et al. Hypersensitivity and idiosyncratic reactions to oxaliplatin. Cancer 2003; 97(9):2301- 7. Abstract

Van Custem E et al. XELOX: Mature results of a multinational, Phase II trial of capecitabine plus oxaliplatin, an effective 1st-line option for patients (pts) with metastatic colorectal cancer (MCRC). Proc ASCO 2003. Abstract 1023.

Wilke H. Future treatment options with capecitabine in solid tumours. Eur J Cancer 2002; 38 Suppl 2:21-5. Abstract

Zeuli M et al. Capecitabine and oxaliplatin in advanced colorectal cancer: A dose-finding study. Ann Oncol 2001;12(12):1737-41. Abstract